Rivaroxaban in atrial fibrillation cardioversion: an update

References

• Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142–1147. doi:10.1016/j.amjcard.2013.05.06323831166
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the american heart association. Circulation. 2017;135(10):e146–e603. doi:10.1161/CIR.000000000000048528122885
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the framingham heart study. Circulation. 1998;98(10):946–952. doi:10.1161/01.CIR.98.10.9469737513
   PubMed Web of Science ®Google Scholar
• Stewart S, Hart CL, Hole DJ, McMurray JJV. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the renfrew/paisley study. Am J Med. 2002;113(5):359–364. doi:10.1016/S0002-9343(02)01236-612401529
   PubMed Web of Science ®Google Scholar
• Andersson T, Magnuson A, Bryngelsson I-L, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case-control study. Eur Heart J. 2013;34(14):1061–1067. doi:10.1093/eurheartj/ehs46923321349
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation–pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356(9244):1789–1794. doi:10.1016/S0140-6736(00)03230-X11117910
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834–1840. doi:10.1056/NEJMoa02137512466507
   PubMed Web of Science ®Google Scholar
• Hagens VE, Van Gelder IC, Crijns HJGM. RAte Control Versus Electrical Cardioversion Of Persistent Atrial Fibrillation (RACE) study group. The RACE study in perspective of randomized studies on management of persistent atrial fibrillation. Card Electrophysiol Rev. 2003;7(2):118–121. doi:10.1023/B:CEPR.0000012398.01150.eb14618033
   PubMedGoogle Scholar
• Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690–1696. doi:10.1016/S0735-1097(03)00332-212767648
   PubMed Web of Science ®Google Scholar
• Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the polish how to treat chronic atrial fibrillation (HOT CAFE) study. Chest. 2004;126(2):476–486. doi:10.1378/chest.126.2.47615302734
   PubMed Web of Science ®Google Scholar
• Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109(12):1509–1513. doi:10.1161/01.CIR.0000121736.16643.1115007003
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. [2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS]. Kardiol Pol. 2016;74(12):1359–1469. doi:10.5603/KP.2016.017228009037
   PubMed Web of Science ®Google Scholar
• Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23(2):208–216.4180019
   PubMed Web of Science ®Google Scholar
• Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol. 1992;19(4):851–855.1545081
   PubMed Web of Science ®Google Scholar
• Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in ca.. - PubMed - NCBI. Available from: https://www.ncbi.nlm.nih.gov/pubmed/14967716. Accessed 1123, 2018
   Google Scholar
• Nelson WW, Desai S, Damaraju CV, et al. International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation. Curr Med Res Opin. 2014;30(12):2437–2442. doi:10.1185/03007995.2014.95782225170587
   PubMed Web of Science ®Google Scholar
• Caldeira D, Cruz I, Morgado G, et al. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. BMC Res Notes. 2014;7:891. doi:10.1186/1756-0500-7-89125491419
   PubMedGoogle Scholar
• Dlott JS, George RA, Huang X, et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation. 2014;129(13):1407–1414. doi:10.1161/CIRCULATIONAHA.113.00260124493817
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi:10.1016/S0140-6736(13)62343-024315724
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi:10.1056/NEJMoa100963821830957
   PubMed Web of Science ®Google Scholar
• Mozos I, Stoian D, Luca CT. Crosstalk between Vitamins A, B12, D, K, C, and E status and arterial stiffness. Dis Markers. 2017;2017:8784971. doi:10.1155/2017/878497128167849
   PubMed Web of Science ®Google Scholar
• Mac-Way F, Poulin A, Utescu MS, et al. The impact of warfarin on the rate of progression of aortic stiffness in hemodialysis patients: a longitudinal study. Nephrol Dial Transplant. 2014;29(11):2113–2120. doi:10.1093/ndt/gfu22424944209
   PubMed Web of Science ®Google Scholar
• Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–977. doi:10.2147/TCRM.S8421026150723
   PubMed Web of Science ®Google Scholar
• Caliskan A, Yavuz C, Karahan O, et al. Factor-Xa inhibitors protect against systemic oxidant damage induced by peripheral-ischemia reperfusion. J Thromb Thrombolysis. 2014;37(4):464–468. doi:10.1007/s11239-013-1019-424218342
   PubMed Web of Science ®Google Scholar
• Gasparova I, Kubatka P, Opatrilova R, et al. Perspectives and challenges of antioxidant therapy for atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol. 2017;390(1):1–14. doi:10.1007/s00210-016-1320-9
   PubMed Web of Science ®Google Scholar
• Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61(19):1998–2006. doi:10.1016/j.jacc.2013.02.02523500298
   PubMed Web of Science ®Google Scholar
• Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131–136. doi:10.1161/CIRCULATIONAHA.110.97754621200007
   PubMed Web of Science ®Google Scholar
• Flaker G, Lopes RD, Al-Khatib SM, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation). J Am Coll Cardiol. 2014;63(11):1082–1087. doi:10.1016/j.jacc.2013.09.06224211508
   PubMed Web of Science ®Google Scholar
• Plitt A, Ezekowitz MD, De Caterina R, Nordio F, Peterson N, Giugliano RP. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol. 2016;39(6):345–346. doi:10.1002/clc.2253727028520
   PubMed Web of Science ®Google Scholar
• Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346–3355. doi:10.1093/eurheartj/ehu36725182247
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Pollack CV, Halperin JL, Piepoli MF, Myers J, Lavie CJ. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39(32):2959–2971. doi:10.1093/eurheartj/ehy14829659797
   PubMed Web of Science ®Google Scholar
• Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995–2003. doi:10.1016/S0140-6736(16)31474-X27590218
   PubMed Web of Science ®Google Scholar
• Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37(14):1145–1153. doi:10.1093/eurheartj/ehv46626330425
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59–7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116(2):180–187. doi:10.1161/CIRCULATIONAHA.106.66802017576867
   PubMed Web of Science ®Google Scholar
• Buller HR, Lensing AWA, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008;112(6):2242–2247. doi:10.1182/blood-2008-05-16014318621928
   PubMed Web of Science ®Google Scholar
• Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention for newly diagnosed and treatment-naive atrial fibrillation patients: an update using 2013–2014 data. J Manag Care Spec Pharm. 2017;23(9):958–967. doi:10.18553/jmcp.2017.23.9.95828854077
   PubMed Web of Science ®Google Scholar
• Trujillo T, Dobesh PP. Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs. 2014;74(14):1587–1603. doi:10.1007/s40265-014-0278-525178252
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–1507. doi:10.1093/europace/euv30926324838
   PubMed Web of Science ®Google Scholar
• Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89–98. doi:doi:10.1111/bcp.1205423294275
   PubMed Web of Science ®Google Scholar
• Salem J-E, Sabouret P, Funck-Brentano C, Hulot J-S. Pharmacology and mechanisms of action of new oral anticoagulants. Fundam Clin Pharmacol. 2015;29(1):10–20. doi:10.1111/fcp.1209125196680
   PubMed Web of Science ®Google Scholar
• Xarelto | European Medicines Agency. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto#product-information-section. Accessed 1123, 2018.
   Google Scholar
• Kreutz R. Pharmacokinetics and pharmacodynamics of rivaroxaban–an oral, direct factor Xa inhibitor. Curr Clin Pharmacol. 2014;9(1):75–83. doi:10.2174/157488470866613111120465824218999
   PubMedGoogle Scholar
• Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: european perspective. Clin Epidemiol. 2014;6:213–220. doi:10.2147/CLEP.S4738524966695
   PubMed Web of Science ®Google Scholar
• Haas S, Bode C, Norrving B, Turpie AG. Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vasc Health Risk Manag. 2014;10:101–114. doi:10.2147/VHRM.S5524624648742
   PubMedGoogle Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393. doi:10.1093/eurheartj/ehy13629562325
   PubMed Web of Science ®Google Scholar
• Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. Circ J. 2012;76(9):2104–2111. doi:10.1253/circj.CJ-12-045422664783
   PubMed Web of Science ®Google Scholar
• Bansilal S, Bloomgarden Z, Halperin JL, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the rivaroxaban once-daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J. 2015;170(4):675–682.e8. doi:10.1016/j.ahj.2015.07.00626386791
   PubMed Web of Science ®Google Scholar
• Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–2394. doi:10.1093/eurheartj/ehr34221873708
   PubMed Web of Science ®Google Scholar
• van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail. 2013;6(4):740–747. doi:10.1161/CIRCHEARTFAILURE.113.00021223723250
   PubMed Web of Science ®Google Scholar
• Jones WS, Hellkamp AS, Halperin J, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J. 2014;35(4):242–249. doi:10.1093/eurheartj/eht49224302273
   PubMed Web of Science ®Google Scholar
• Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011;17(1):25–39. doi:10.18553/jmcp.2011.17.1.2521204588
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Cappato R, Ezekowitz MD, et al. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial. Europace. 2016;18(2):184–190. doi:10.1093/europace/euv29426487668
   PubMed Web of Science ®Google Scholar
• Jacobs MS, de Jong LA, Postma MJ, Tieleman RG, van Hulst M. Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation. Eur J Health Econ. 2018;19(7):957–965. doi:10.1007/s10198-017-0942-229181817
   PubMed Web of Science ®Google Scholar
• Camm AJ, Turpie AGG, Hess S, et al. Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. Europace. 2018;20(6):e87–e95. doi:10.1093/europace/eux12729016755
   PubMed Web of Science ®Google Scholar
• Itäinen S, Lehto M, Vasankari T, et al. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion. Europace. 2018;20(4):565–568. doi:10.1093/europace/eux11629016758
   PubMed Web of Science ®Google Scholar
• Femia G, Fetahovic T, Shetty P, Lee A. Novel oral anticoagulants in direct current cardioversion for Atrial Fibrillation. Heart Lung Circ. 2018;27(7):798–803. doi:10.1016/j.hlc.2017.06.72628802808
   PubMed Web of Science ®Google Scholar
• Russo V, Di Napoli L, Bianchi V, et al. A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: the MonaldiVert real life experience. Int J Cardiol. 2016;224:454–455. doi:10.1016/j.ijcard.2016.09.02227716588
   PubMed Web of Science ®Google Scholar
• Russo V, Rago A, Papa AA, et al. Budget impact analysis of rivaroxaban vs. warfarin anticoagulation strategy for direct current cardioversion in non-valvular atrial fibrillation patients: the MonaldiVert economic study. Minerva Cardioangiol. 2018;66(1):1–5. doi:10.23736/S0026-4725.17.04500-528948752
   PubMed Web of Science ®Google Scholar
• Papp J, Zima E, Bover R, et al. Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. Eur Heart J Cardiovasc Pharmacother. 2017;3(3):147–150. doi:10.1093/ehjcvp/pvx00328329309
   PubMed Web of Science ®Google Scholar
• Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755–759. doi:10.1016/0003-4975(95)00887-X8572814
   PubMed Web of Science ®Google Scholar
• Scherr D, Dalal D, Chilukuri K, et al. Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2009;20(4):379–384. doi:10.1111/j.1540-8167.2008.01336.x19017348
   PubMed Web of Science ®Google Scholar
• Wallace TW, Atwater BD, Daubert JP, et al. Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2010;21(8):849–852. doi:10.1111/j.1540-8167.2010.01729.x20158561
   PubMed Web of Science ®Google Scholar
• Anselmino M, Garberoglio L, Gili S, et al. Left atrial appendage thrombi relate to easily accessible clinical parameters in patients undergoing atrial fibrillation transcatheter ablation: a multicenter study. Int J Cardiol. 2017;241:218–222. doi:10.1016/j.ijcard.2017.04.01428413114
   PubMed Web of Science ®Google Scholar
• Bernhardt P, Schmidt H, Hammerstingl C, et al. Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance imaging. Am J Cardiol. 2004;94(6):801–804. doi:10.1016/j.amjcard.2004.06.01015374795
   PubMed Web of Science ®Google Scholar
• Wyrembak J, Campbell KB, Steinberg BA, et al. Incidence and predictors of left atrial appendage thrombus in patients treated with nonvitamin K oral anticoagulants versus warfarin before catheter ablation for atrial fibrillation. Am J Cardiol. 2017;119(7):1017–1022. doi:10.1016/j.amjcard.2016.12.00828153350
   PubMed Web of Science ®Google Scholar
• Zylla MM, Pohlmeier M, Hess A, et al. Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter. Am J Cardiol. 2015;115(5):635–640. doi:10.1016/j.amjcard.2014.12.01625591898
   PubMed Web of Science ®Google Scholar
• Gawałko M, Kapłon-Cieślicka A, Budnik M, et al. Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion. Pol Arch Intern Med. 2017;127(12):823–831. doi:10.20452/pamw.411728972957
   PubMedGoogle Scholar
• Bertaglia E, Anselmino M, Zorzi A, et al. NOACs and atrial fibrillation: incidence and predictors of left atrial thrombus in the real world. Int J Cardiol. 2017;249:179–183. doi:10.1016/j.ijcard.2017.07.04829121724
   PubMed Web of Science ®Google Scholar
• Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The stroke prevention in atrial fibrillation investigators committee on echocardiography. Ann Intern Med. 1998;128(8):639–647.9537937
   PubMedGoogle Scholar
• Lee W-C, Fang C-Y, Chen Y-L, et al. Left atrial or left atrial appendage thrombus resolution after adjustment of oral anticoagulant treatment. J Stroke Cerebrovasc Dis. 2018. doi:10.1016/j.jstrokecerebrovasdis.2018.09.015
   Web of Science ®Google Scholar
• Lip GYH, Hammerstingl C, Marin F, et al. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126–134. doi:10.1016/j.ahj.2016.05.00727502860
   PubMed Web of Science ®Google Scholar
• Niku AD, Shiota T, Siegel RJ, Rader F. Prevalence and resolution of left atrial thrombus in patients with nonvalvular atrial fibrillation and flutter with oral anticoagulation. Am J Cardiol. 2018. doi:10.1016/j.amjcard.2018.09.027
   PubMed Web of Science ®Google Scholar
• Hammerstingl C, Pötzsch B, Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost. 2013;109(4):583–584. doi:10.1160/TH12-11-082123348106
   PubMed Web of Science ®Google Scholar
• Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial. J Stroke Cerebrovasc Dis. 2014;23(2):379–383. doi:10.1016/j.jstrokecerebrovasdis.2013.07.02123954611
   PubMed Web of Science ®Google Scholar
• Takasugi J, Yamagami H, Okata T, Toyoda K, Nagatsuka K. Dissolution of the left atrial appendage thrombus with rivaroxaban therapy. Cerebrovasc Dis. 2013;36(4):322–323. doi:10.1159/00035431524192983
   PubMed Web of Science ®Google Scholar
• Beppu S, Nimura Y, Sakakibara H, Nagata S, Park YD, Izumi S. Smoke-like echo in the left atrial cavity in mitral valve disease: its features and significance. J Am Coll Cardiol. 1985;6(4):744–749.4031288
   PubMed Web of Science ®Google Scholar
• Saito S, Tomita H, Kimura Y, et al. Reduced smoke-like echo and resolved thrombus in the left atrium with rivaroxaban therapy in an acute cardioembolic stroke patient. J Stroke Cerebrovasc Dis. 2014;23(6):1747–1749. doi:10.1016/j.jstrokecerebrovasdis.2014.01.01424725815
   PubMed Web of Science ®Google Scholar
• Scarano M, Casale M, Mantini C, et al. Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report. J Med Case Rep. 2017;11. doi:10.1186/s13256-017-1249-8
   PubMedGoogle Scholar
• Pizzi LT, Toner R, Foley K, et al. Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery. Pharmacotherapy. 2012;32(6):502–514. doi:10.1002/j.1875-9114.2012.01101.x22570188
   PubMed Web of Science ®Google Scholar
• Varin R, Mirshahi S, Mirshahi P, et al. Whole blood clots are more resistant to lysis than plasma clots–greater efficacy of rivaroxaban. Thromb Res. 2013;131(3):e100–e109. doi:10.1016/j.thromres.2012.11.02923313382
   PubMed Web of Science ®Google Scholar
• Habara S, Dote K, Kato M, et al. Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation. Eur Heart J. 2007;28(18):2217–2222. doi:10.1093/eurheartj/ehm35617716991
   PubMed Web of Science ®Google Scholar
• Lip GY, Rumley A, Dunn FG, Lowe GD. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Int J Cardiol. 1995;51(3):245–251.8586473
   PubMed Web of Science ®Google Scholar
• Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med. 2008;14(10):429–440. doi:10.1016/j.molmed.2008.08.00118774340
   PubMed Web of Science ®Google Scholar
• Miyazawa K, Pastori D, Hammerstingl C, et al. Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA). Ann Med. 2018:1–27. doi:10.1080/07853890.2018.1495337
   PubMed Web of Science ®Google Scholar
• Cowell RPW. Direct oral anticoagulants: integration into clinical practice. Postgrad Med J. 2014;90(1067):529–539. doi:10.1136/postgradmedj-2013-13247425012514
   PubMed Web of Science ®Google Scholar
• Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(3):623–627. doi:10.1111/jth.1322726911798
   PubMed Web of Science ®Google Scholar
• Heo Y-A. Andexanet alfa: first global approval. Drugs. 2018;78(10):1049–1055. doi:10.1007/s40265-018-0940-429926311
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor xa inhibitors. N Engl J Med. 2019. doi:10.1056/NEJMoa1814051
   Web of Science ®Google Scholar
• Ollier E, Hodin S, Lanoiselée J, et al. Effect of activated charcoal on rivaroxaban complex absorption. Clin Pharmacokinet. 2017;56(7):793–801. doi:10.1007/s40262-016-0485-127910037
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2014;64(21):e1–e76. doi:10.1016/j.jacc.2014.03.02224685669
   PubMed Web of Science ®Google Scholar
• Goto M, Miura S-I, Suematsu Y, et al. Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice. Int J Cardiol. 2016;220:602–607. doi:10.1016/j.ijcard.2016.06.21227390997
   PubMed Web of Science ®Google Scholar
• Imano H, Kato R, Tanikawa S, et al. Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia. J Pharmacol Sci. 2018;137(3):274–282. doi:10.1016/j.jphs.2018.07.00230055890
   PubMed Web of Science ®Google Scholar
• Moñux G, Zamorano-León JJ, Marqués P, et al. FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms. Br J Clin Pharmacol. 2017;83(12):2661–2670. doi:10.1111/bcp.1338328735510
   PubMed Web of Science ®Google Scholar